Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Arcus Biosciences (NYSE:RCUS) and maintained a price target of $30.
October 03, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Arcus Biosciences and maintained a $30 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $30 price target by a reputable analyst suggests a positive outlook for Arcus Biosciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100